Promises of Biomarkers in Drug Development – A Reality Check
- 18 June 2007
- journal article
- review article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 69 (6) , 381-394
- https://doi.org/10.1111/j.1747-0285.2007.00522.x
Abstract
Biomarkers have been a buzz word in drug development for the last 5 years. But where do we stand now? This perspective article will demonstrate to which extent biomarkers have impacted drug development and the use of drugs. In particular, the different types of biomarkers, their identification, validation and use in different phases of drug development from drug discovery, to approval, to clinical application will be discussed as well as the state-of-the-art biomarker technologies and promising future methods. The high interest in biomarkers has generated the need for development of new technologies and refinement of existing ones. Besides discussing their perspectives of applications, the present article also illustrates the future of biomarker development in terms of qualification for regulatory use and co-development.Keywords
This publication has 49 references indexed in Scilit:
- A cost-effectiveness approach to the qualification and acceptance of biomarkersNature Reviews Drug Discovery, 2006
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- Diagnostics and biomarker development: priming the pipelineNature Reviews Drug Discovery, 2006
- Individualised cancer therapeutics: dream or reality?Emerging Therapeutic Targets, 2005
- Warfarin: a case history in pharmacogeneticsHeart, 2005
- Jonathan K. C. Knowles discusses the impact of pharmacogenomics on market segmentationNature Reviews Drug Discovery, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health StudyArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Toxicology and genetic toxicology in the new era of “toxicogenomics”: impact of “-omics” technologiesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001